Stryker has recalled its LifePak 15 defibrillator-monitor system because it may lock up after delivering a shock to a patient. The defibrillator was originally made by Physio-Control, before being purchased by Stryker.

February 4, 2019 — Stryker announced Feb. 1, the company is launching a voluntary field action on specific units of the LifePak 15 Monitor/Defibrillators. The company is notifying certain customers of an issue that may cause the device to lock up after a defibrillation shock is delivered. 

Paragonix Technologies Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) for a design enhancement allowing for the use of the Paragonix SherpaPak Cardiac Transport System (CTS) with small and pediatric donor hearts. Starting in Q1 2019, the system will now be shipped with heart connectors covering most aortic diameters, permitting the anchoring of various size hearts including small pediatric hearts to its proprietary suspension system for improved donor heart transport.

A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a new model that would reduce the need for bypass surgery, heart transplants or artificial pumping devices.

Two of the top news items from January included news atrial fibrillation guidelines that now recommend new anticoagulants (NOACs) over warfarin, and the FDA warning hospitals about the increased mortality found in one study involving pacitaxel-eluting stents and balloon devices for the peripheral arteries.

February 1, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of January 2019. This is based on website’s record 272,495 pageviews for the month:

 

1. The Most Popular Cardiology Topics in 2018

Merit Medical Systems Inc. announced that the PreludeSync Distal Compression Device is now available in the United States, European, Middle Eastern, African and Asia-Pacific markets. The device is the first specifically designed to achieve hemostasis of the radial artery during procedures where access is gained via the distal radial artery.

Advanced Revascularization (ARCH) Symposium

Cardiovascular Systems Inc. announced that the first patients in the United States were treated using the OrbusNeich Teleport Microcatheter (Teleport), which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now